Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02794857 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation
A Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Neuraltus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 138
- Enrollment target
- 20
- Study locations
NCT02794857 is a Phase 2 study of Amyotrophic Lateral Sclerosis that has completed, run by Neuraltus Pharmaceuticals. The registered enrollment target is 138 participants, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT02794857, a Phase 2 study of Amyotrophic Lateral Sclerosis, has completed, sponsored by Neuraltus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 138 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates NP001 in patients with amyotrophic lateral sclerosis (ALS) and evidence of systemic inflammation. Half of participants will receive NP001 and the other half will receive placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NP001
Study Locations (20)
California
- Cedars-Sinai Medical Center - Los Angeles
- University of California, Irvine, Department of Neurology - Orange
- Forbes Norris MDA/ALS Research Center, CPMC - San Francisco
Arizona
- St. Joseph's Hospital and Medical Center - Barrow Neurology Clinics - Phoenix
- Mayo Clinic Arizona - Scottsdale
Florida
- Mayo Clinic Florida - Jacksonville
- University of Miami Miller School of Medicine - Miami
North Carolina
- Carolinas Medical Center, Neurosciences Instutite-Neurology - Charlotte
- Duke Neurological Disorders Clinic at Morreene Road - Durham
Ohio
- Cleveland Clinic Foundation-Cleveland Clinic Hospital - Cleveland
- The Ohio State University Wexner Medical Center - Columbus
Georgia
- Emory University, Department of Neurology - Atlanta
Kansas
- University of Kansas Medical Center - Kansas City
Kentucky
- University of Kentucky, Albert B. Chandler Medical Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2016-08-29 |
| Est. Completion | 2017-12-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02794857
The ClinicalTrials.gov registry entry for NCT02794857 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (85% lower). The listed sponsor is Neuraltus Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02794857 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT02794857 about?
NCT02794857 is a clinical study titled "Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation". This study evaluates NP001 in patients with amyotrophic lateral sclerosis (ALS) and evidence of systemic inflammation. Half of participants will receive NP001 and the other half will receive placebo.
What is the current status of trial NCT02794857?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 138 participants. The study started on 2016-08-29. Estimated completion is 2017-12-12.
What conditions does trial NCT02794857 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT02794857?
The interventions under investigation include: Placebo (DRUG), NP001 (DRUG).
Who is sponsoring clinical trial NCT02794857?
This trial is sponsored by Neuraltus Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02794857 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
RECRUITING · Phase 2
-
HEALEY ALS Platform Trial - Master Protocol
RECRUITING · Phase 2
-
RAPA-501 Therapy for ALS
RECRUITING · Phase 2
-
A Study of Ranolazine in ALS
RECRUITING · Phase 2
-
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.